Journal Pre-proof

The Sac Evolution Imaging Follow-Up after EVAR: an international expert opinion-based Delphi consensus study

Giovanni Tinelli, MD, PhD, Mario D'Oria, MD, Simona Sica, MD, Kevin Mani, MD, PhD, Zoran Rancic, MD, PhD, Timothy Andrew Resh, MD, Flavia Beccia, MD, Ali Azizzadeh, MD, Marcelo Martins Da Volta Ferreira, MD, Mauro Gargiulo, MD, PhD, Sandro Lepidi, MD, Yamume Tshomba, MD, Gustavo S. Oderich, MD, FACS, Stephan Haulon, MD, PhD, SLIM F-U EVAR Collaborative Study Group

Please cite this article as: Tinelli G, D'Oria M, Sica S, Mani K, Rancic Z, Resh TA, Beccia F, Azizzadeh A, Da Volta Ferreira MM, Gargiulo M, Lepidi S, Tshomba Y, Oderich GS, Haulon S, SLIM F-U EVAR Collaborative Study Group, The Sac Evolution Imaging Follow-Up after EVAR: an international expert opinion-based Delphi consensus study, *Journal of Vascular Surgery* (2024), doi: https://doi.org/10.1016/j.jvs.2024.03.007.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Title:**

2 **The Sac Evolution Imaging Follow-Up after EVAR: an international expert opinion-based**

3 **Delphi consensus study**

4

5 **Short Title:**

6 Sac evoLution IMaging Follow-Up after EVAR (SLIM F-U EVAR)

7

8 **Authors:**

9 Giovanni Tinelli[1], MD, PhD, Mario D'Oria[2], MD, Simona Sica[1], MD, Kevin Mani[3], MD, PhD

10 Zoran Rancic[4], MD, PhD, Timothy Andrew Resh[5], MD, Flavia Beccia[6], MD, Ali Azizzadeh[7], MD,

11 Marcelo Martins Da Volta Ferreira[8], MD, Mauro Gargiulo[9], MD, PhD, Sandro Lepidi,[2] MD,

12 Yamume Tshomba[1], MD, Gustavo S Oderich[10], MD, FACS, Stephan Haulon[11], MD, PhD; SLIM

13 F-U EVAR Collaborative Study Group

14

15 **Affiliations**

16 1. Università Cattolica del Sacro Cuore, Rome, Italy; Unit of Vascular Surgery, Fondazione

17   Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy

18 2. Division of Vascular and Endovascular Surgery, Cardiovascular Department, University

19   Hospital of Trieste, Trieste, Italy

20 3. Section of Vascular Surgery, Department of Surgical Sciences, Uppsala University,

21   Uppsala, Sweden

22 4. University of Zurich, Zurich, Switzerland

23 5. Copenhagen University Hospital, Denmark

24 6. Section of Hygiene and Public Health, Department of Life Sciences and Public Health,

25   Università Cattolica del Sacro Cuore, Rome, Italy

1 7. Division of Vascular Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los

2 Angeles, California, USA

3 8. Vascular division, São José Hospital, Rio de Janeiro

4 9. Vascular Surgery University of Bologna, Vascular Surgery Unit IRCCS University

5 Hospital Policlinico S. Orsola Bologna, Italy

6 10. Department of Cardiothoracic and Vascular Surgery, University of Texas Health Science

7 Center at Houston, Houston, Texas, USA

8 11. Hôpital Marie Lannelongue, GHPSJ, Université Paris Saclay, Paris, France

9

10 **Article Type:** Original Research Article, International Collaboration

11

12 **Abstract Word Count: 257**

13 **Text Body Word Count: 3074**

14 **Number of tables and figures: 4**

15

18

19 **Conflict of interest statement:** none.

20

21 **Corresponding Author and Post-Publication Corresponding Author**

22 Giovanni TINELLI, MD, PhD

23 Università Cattolica del Sacro Cuore, Rome, Italy; Unit of Vascular Surgery, Fondazione

24 Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy

1   Email: giovanni.tinelli@policlinicogemelli.it

2   Address: Largo Agostino Gemelli, 8 00168 Rome, Italy

3   Mobile: +393474864020

4   Twitter: @gio_tinelli

5

7

8

1   Email: giovanni.tinelli@policlinicogemelli.it

2   Address: Largo Agostino Gemelli, 8 00168 Rome, Italy

1 **<u>ARTICLE HIGHLIGHTS</u>**

2 **Type of Research:** Multicenter Expert Consensus Delphi study

3 **Key Findings:** Fifteen statements (55.6%) were classified as grade I, while twelve (44.4%) were

4 classified as grade II.

5 **Take home Message:** Experts agreed that sac regression should be considered an important

6 indicator of EVAR success and always be assessed during follow-up after EVAR

7

8 **<u>Table of Contents Summary</u>**

9 Currently, there are no surveillance protocols related to aneurysm shrinkage after EVAR.

10 The present international expert-based Delphi consensus document details the practices endorsed

11 at high volume aortic centres, creating the basis for future studies, and highlighting the need for

12 dedicated reporting standards in future guidelines.

1 **Abstract**

2 **Objective.** Management of follow-up protocols after endovascular aortic repair (EVAR), vary

3 significantly between centres and is not standardized according to the sac regression. By designing

4 an international expert-based Delphi consensus, the study aimed to create recommendations on

5 follow-up after EVAR according to sac evolution.

6 **Methods.** Eight facilitators created appropriate statements regarding the study topic that were

7 voted, using a 4-point Likert scale, by a selected panel of international experts using a three-

8 round modified Delphi consensus process. Based on the experts' responses, only those

9 statements reaching a Grade A (full agreement ≥75%) or B (overall agreement ≥80% and full

10 disagreement <5%) were included in the final document.

11 **Results.** One-hundred and seventy-four participants were included in the final analysis, and

12 each voted the initial 29 statements related to the definition of sac regression (Q1-Q9), EVAR

13 follow-up (Q10-Q14), and the assessment and role of sac regression during follow-up (Q15-

14 Q29). At the end of the process, 2 statements (6.9%) were rejected, 9 statements (31%) received

15 a grade B consensus strength, and 18 (62.1%) reached a grade A consensus strength. Out of

16 twenty-seven final statements, fifteen statements (55.6%) were classified as grade I, while

17 twelve (44.4%) were classified as grade II. Experts agreed that sac regression should be

18 considered an important indicator of EVAR success and always be assessed during follow-up

19 after EVAR.

20 **Conclusions.** Based on the elevated strength and high consistency of this international expert-

21 based Delphi consensus, most of the statements might guide current clinical management of

22 follow-up after EVAR according to the sac regression. Future studies are needed to clarify

23 debated issues.

1 **Introduction**

2

3 Endovascular aneurysm repair (EVAR) is the preferred choice of treatment for abdominal

4 aortic aneurysm (AAA) in suitable patients, with reduced perioperative mortality compared

5 with open repair.[1-3]

6 Current recommendations from the Society for Vascular Surgery (SVS) for surveillance after

7 EVAR include a Computed Tomography Angiography (CTA) scan at 1 month, and an annual

8 duplex ultrasound study if the initial CTA showed no endoleak.[4] According to the European

9 Society for Vascular Surgery (ESVS) guidelines, all patients should be offered lifelong follow

10 up after EVAR, including a CTA scan at least every 5 years due to the risk of late failure and

11 aneurysm progression. If necessary, more frequent imaging may be performed with CTA or

12 duplex ultrasound based on the risk stratification of late complications after the first post-

13 operative examination.[5,6]

14 Aneurysm sac shrinkage following EVAR has been proposed to indicate successful aneurysm

15 exclusion, and to be associated with significantly lower risk of mortality, reinterventions rate

16 and improved outcomes.[7-11]

17 Nevertheless, follow-up protocols vary significantly between centres regarding both modality

18 and frequency and there are no surveillance protocols related to aneurysm sac shrinkage

19 following EVAR.

20 Using an international expert-based Delphi consensus, this paper aims to investigate the

21 practices endorsed at high-volume aortic centers and create recommendations on follow-up

22 after EVAR according to sac evolution.

23

24 **Methods**

1 *Study design.* A modified Delphi consensus process, following the methodology applied in

2 prior literature, was used to obtain expert consensus on the role of sac regression during follow-

3 up after EVAR.[12]

4 All surveys were submitted online and recorded through SurveyMonkey® (https:

5 //www.surveymonkey.com). Invited experts were unaware of the identity of any other

6 members of the international panel.

7 Institutional Review Board approval was not required due to the nature of the study (not

8 involving patients data).

9 *Core Team & Selection of the panel of international experts.* The members of the Core Team

10 were identified among the study principal investigators (Authors: GT, MD, SS,). To ensure

11 proper statistical analysis, a professional biostatistician with prior experience in Delphi-based

12 research was also invited to join the Core Team (Author: FB). Potential international experts

13 to be included as panel members were selected among active physicians with specialization in

14 vascular surgery or interventional radiology practicing in Europe, America, Asia, and Oceania.

15 Physicians were identified based on prior publications in high-ranked vascular scientific

16 journals and/or from international conferences' presentations on endovascular procedures,

17 and/or among researchers serving on editorial boards for peer-reviewed journals relevant to the

18 study practice. To be eligible for the expert panel, physicians were required to practice in a

19 department that had performed more than 50 endovascular aortic cases yearly and they had

20 demonstrated competence as first operator with more than 50 EVAR procedures during their

21 career.

22 *Delphi methodology.* A modified Delphi method was used to construct the expert consensus.[13]

23 To develop the initial lists of statements for expert evaluation, a preliminary exploratory

1 questionnaire (with multiple choice questions and option for open-ended suggestions) was

2 administered to investigate the daily practice of follow-up after EVAR at each center or

3 division. The answers provided by the questionnaire were analysed by the Core Team, and the

4 statements were designed accordingly. A compressed four-point Likert-type scale was used to

5 grade statements based on the level of agreement: agree (score 1), somewhat agree (score 2),

6 somewhat disagree (score 3), disagree (score 4). The central fifth grade of the Likert scale (eg.

7 "no opinion") was omitted in view of the panel expertise and based on the assumption that

8 invited experts would be able to offer their opinion for each statement. An open-ended question

9 was used to guide changes to statements during the first two rounds. The statements were

10 submitted to three rounds for evaluation, and eventually modified by the Core Team to increase

11 consensus according to the experts' open comments during the first two rounds. The first round

12 was intended to submit the first formulation of the statements and collect a broad indication of

13 the consensus strength. The second round was intended to obtain a detailed estimate of the

14 consensus change from the original formulations to the modified formulations after they had

15 been implemented as per the above process. The third round was intended to confirm the

16 strength of consensus from the second to the third formulation

17

18 *Statistical analysis, Evaluation of consensus strength & Consistency of scoring.* Statistical

19 analysis was performed with STATA 17.0 software (Stata Corporation, College Station, TX,

20 USA).

21 The statements were tested in a three-round Delphi, using a 4-point Likert scale. The proportion

22 of experts rating a single item with a score of 1 "Agree" or 2 "Somewhat agree" compared with

23 the total number of experts involved determined the Content Validity Index (CVI), which

24 ranged from 0% to 100%.

1 At consensus, the statements were evaluated according to the strength of agreement, and the

2 consistency ranking, calculated from the previous round. The methodology is reported in Table

3 I.

4 In addition to the agreement, the mean score and standard deviation, the significance of the

5 change from the previous round according to Wilcoxon's test and Pearson's correlation were

6 evaluated. These items were used to confirm the strength of consensus. A p-value <0.25 was

7 considered a significant variation, considering that some degree of multiplicity was expected.

8 Consistency was assessed by considering intraclass correlation coefficients and p-values,

9 Cohen's kappa, and Fleiss' pi and test-rest reliability by Bland-Altman plot.

10 The proportion of ratings exceeding the critical difference was estimated to monitor test-retest

11 reliability according to Bland and Altman and was considered as a modifier of consistency: a

12 proportion of outliers above 10 percent was considered indicative of significant heterogeneity

13 among the experts and was used as a cut-off for downgrading consistency.

14 At the time of consensus, statements with strength grades A and B were considered of sufficient

15 quality to be included in the final set of recommendations.

16

17 *Criteria for selection or change of statements selection.* The decision to refuse or modify and

18 resubmit a statement was taken based on a composite of different statistical criteria. The

19 predefined criteria for submission/resubmission after the first round was set as follows:

20 statements with a proportion of full disagreement ≥10% and/or a mean score <2.0 were not

21 resubmitted; all other statements were resubmitted after textual adaptations and/or statements

22 merging, as appropriate. The predefined criteria for submission/resubmission after the second

23 round was set as follows:

24   a. statements with a proportion of overall agreement <80% and a proportion of full

25 disagreement >5% (Grade C and D) were removed from the consensus;

1   b. statements with at least five among: a proportion of "fully agree" >75% or a

2   proportion of overall agreement >80%, a proportion of full disagreement <5%, a mean score

3   change from first to second round not statistically significant (Wilcoxon test – see above), a

4   significant score correlation between first and second round, a significant measure of

5   agreement (Cohen's k – see above), a significant intraclass correlation coefficient set for

6   consistency, and a good test-retest reliability, were to be accepted in their current form, unless

7   suggestions from the Core team recommended resubmission.

8   At the third and last round, only statements with grade of strength A and B were considered of

9   sufficient quality to be included in the final set of recommendations.

10

11   **Results**

12   *Overview of participants and flow of Delphi exercise.* Three-hundred and forty-three experts

13   were initially contacted and invited to participate in the SLIM-FU study. One-hundred and

14   seventy-four participants, all meeting the pre-specified inclusion criteria, actively answered to

15   all the three Delphi the survey rounds; 181 experts completed Round 1, and 177 completed

16   Round 2.

17   The Core Team members designed 29 initial statements for the first round related to the

18   definition of sac regression (Q1-Q9), EVAR follow-up (Q10-Q14), and the assessment and

19   role of sac regression during follow-up (Q15-Q129). After round 1, eighteen statements were

20   modified (Q3, Q6-Q10, Q12, Q14, Q16, Q19-Q21, Q24-Q29); after round 2, two statements

21   were rejected (Q9 and Q27).

22   Table II summarizes the proportion of consensus obtained by each statement at the third round.

23   At the end of the process, 2 statements (6.9%) were rejected, 9 statements (31%) received a

24   grade B consensus strength, and 18 statement (62.1%) reached a grade A consensus strength.

1 Table III summarizes the estimates of overall consistency across rounds estimated using

2 Cohen's kappa and Fleiss' pi evaluation. Out of twenty-seven final statements, fifteen

3 statements (55.6%) were classified as grade I, while twelve (44.4%) were classified as grade

4 II. No grade III-IV statements were reported.

5 The complete text of 27 statements that received a Grade A or Grade B consensus and, in the

6 formulation, submitted to the final round are listed in Table IV.

7

8 *Definition of sac regression and its prognostic relevance.* The experts suggested (Grade A) that

9 sac regression should be defined as reduction in maximum diameter of the aneurysm sac by ≥

10 5 mm (statement 1). According to the experts' opinion, aneurysm sac regression should be

11 considered an important indicator of EVAR success (Grade A) and different dedicated

12 statements regarding its role (statements 3-8) were voted. Aneurysm sac regression is usually

13 correlated to the absence of:

14   - endoleaks (I-III) that require secondary intervention after EVAR

15   - secondary intervention

16   - aneurysm rupture

17   - aneurysm-related mortality (Grade A)

18 Grade B agreement was reached (statement 7) regarding the correlation to low rates of

19 aneurysm-related complications after EVAR.

20

21 *Follow-up after EVAR.* The first follow-up after patient discharge following an elective EVAR

22 should be a DUS or CT-angiography within 3 months (Grade A, Consistency II). Experts

23 identified different statements (11,12,14) with high strength (Grade A) and consistency (I)

24 regarding the follow-up: the imaging modality should be a DUS or a CTA (if DUS is not

25 available or not diagnostic) at 1-year, 2-year, and 5-year follow-up.

1

2 *Assessment and role of sac regression during follow-up*. According to the experts' opinion, sac

3 regression should always be assessed during follow-up after EVAR (Statement 15 - grade A).

4 A DUS or a CTA should be used as first-line imaging modality to assess sac regression during

5 follow-up (Grade A, Consistency II). However, the comparison of two CTA (baseline vs

6 follow-up) is the most accurate imaging to detect sac regression after EVAR. In case of DUS

7 imaging modality, the sac regression should be measured in two projections at least; in case of

8 CTA imaging modality, the sac regression should be measured on the orthogonal axis using a

9 dedicated reconstruction software (Statement 18, 19 – grade A).

10 The experts agree that sac regression can be usually expected to occur within 2 years after

11 EVAR, and that a diameter change within ± 4.9 mm may be considered a clinically relevant

12 parameter during follow-up (Statement 21, 22 – grade B). However, a grade A agreement was

13 reached (statement 23) regarding the clinically relevance of sac increase (diameter change ≥ 5

14 mm).

15 In the case of sac regression, the follow-up protocol after EVAR should be continued

16 (Statement 24 - Grade B, Consistency I). However, in case of EVAR within the instruction for

17 use, sac regression is one of the parameters to consider for possible follow-up protocol changes

18 (Statement 26 - Grade B, Consistency I).

19 Volumetric analysis and machine learning models may represent, in the future, an adjunctive

20 tool to analyse AAA sac evolution during follow-up after EVAR (Statement 28, 29 – grade B).

21

22 **Discussion**

23 Endovascular treatment of abdominal aortic pathologies has evolved over the last two decades

24 to the point of being the current first-line treatment modality for a large proportion of

25 patients.[4,14] Owing to the inherent risk of endograft-related complications and secondary

1   rupture that may occur during extended follow-up after EVAR, regular imaging surveillance is

2   mandatory and dedicated recommendations have been formulated by vascular societies of

3   Europe and North America.[4,5,15] However, several unanswered questions remain, including the

4   true benefits of prophylactic regular imaging follow-up after EVAR. Furthermore, despite clear

5   guidelines, follow-up routines may vary significantly between centres and some of this

6   variability may be related to heterogeneity in the imaging metrics used to assess EVAR

7   success.[16]

8   Our international expert-based Delphi exercise was able to achieve a remarkable consensus

9   amongst a large group of EVAR experts regarding the importance of sac regression as a marker

10   for EVAR success and clarify experts' opinions regarding its definitions, assessment, and

11   natural history. Sac shrinkage during follow-up indicates successful exclusion of the aneurysm

12   from arterial pressure, and has been consistently shown to be a predictor of low risk of EVAR

13   failure and overall mortality during post-operative follow-up.[9,17-19]

14   To the authors' knowledge, this is the first study to report a pragmatic approach to establish

15   broad expert-based consensus on sac regression post-EVAR. The majority of experts agreed

16   on several key aspects including but not limited to: the definition of sac regression as more

17   than 5 mm as compared to baseline, the expectancy of sac regression to occur within the first

18   two years after EVAR, the use of CTA as the optimal method to analyse sac regression, and

19   the association of sac regression with the absence of clinically-relevant endoleaks. It should be

20   underlined that there is a broad consensus that assessment of sac regression should be

21   performed at each EVAR follow-up, and that this assessment should be performed

22   systematically both on CTA and DUS with a defined methodology, that compared diameter of

23   the aneurysm at time of measurement to previous measurements including the baseline

24   evaluation close to the time of repair. Sac regression should be included in a broader evaluation

25   of the patient-specific risk profile for EVAR failure which include details of aortic anatomy

1 and specific endograft characteristics. Further evidence from prospective trials is still needed

2 to define more tailored follow-up protocols that could be safely end cost-effectively

3 implemented by taking into consideration sac regression.

4 Our findings correlate well with available evidence surrounding the incidence and role of sac

5 regression in EVAR patients. A large observational study conducted in Japan documented

6 cumulative rates of sac regression (>5 mm) at 1 year and 5 years in 50% and 62% of patients,

7 respectively.[20] Similarly, a study from Ontario demonstrated a pattern of sac diameter change

8 after EVAR, with the majority of sac regression occurring within the first 2 years.[21] Finally,

9 other studies have identified that early sac regression of greater than 5 mm within 1 to 2 years

10 after implantation was associated with a significantly lower probability for delayed sac

11 expansion, although a small proportion of patients would still go on to develop delayed sac

12 expansion.[7, 19-22] In fact, variability in sac regression can also be influenced by non-anatomic

13 variables including age, sex, and original AAA diameter, even after controlling for the presence

14 or absence of an endoleak. Indeed, the ultimate biophysical relationship between specific

15 endograft design and materials, and sac regression is yet to be determined.[21,23-25]

16 ESVS guidelines stratify patients after EVAR in low, intermediate, and high risk groups based

17 on presence of endoleaks, adequate sealing and overlap zones, anatomy within Instructions for

18 Use (IFU), and sac shrinkage.[5] In patients with adequate seal, no endoleak type I or III, but

19 with presence of endoleak type II, sac evolution determinates patient's follow-up: if there is

20 expansion ≥ 1 cm, the evaluation for re-intervention is suggested; if the shrinkage is ≥ 1 cm

21 instead of annual DUS, CTA at least every 5 years is suggested.

22 In the present study experts agreed that CTA is the most accurate imaging modality to detect

23 sac regression after EVAR. A metanalysis comparing DUS and CTA showed that the pooled

24 sensitivity and specificity of DUS were 0.77 and 0.94, respectively.[26] Compared to CTA, it is

25 reported that DUS has an overall lower sensitivity in the follow-up of patients after EVAR with

1   39% of positive predictive value.[27] However, DUS offers several potential advantages,

2   including lower cost, no radiation exposure, shorter scan times and the lack of any toxicity risk.

3   Despite the widespread application of DUS worldwide, no recommendations have been

4   published regarding the preferred method of maximum abdominal aortic diameter

5   measurement that obtains the most reproducible aortic dimensions.[28]

6   In the current Delphi process, the participants agreed that during EVAR follow-up at 3 months,

7   1, 2, 3 and 5-years, imaging modality should be DUS or CTA if DUS is not available or not

8   diagnostic. As the focus of the current consensus process was not to assess imaging frequency

9   during follow-up, we cannot comment on the expert opinion on imaging frequency in patients

10 with low risk for EVAR failure, including patients with significant sac shrinkage already early

11 during follow-up. As agreed in the Delphi process, future development of AI-based tools that

12 may automate both evaluation of sac dynamics as well as post-EVAR seal zone and endoleak

13 evaluation may facilitate decision making regarding EVAR follow-up algorithms.[29]

14 Interestingly, the expert panel did not rate the use of artificial intelligence (AI) and machine

15 learning as very strong and with very high consistency. AI could reduce human error in

16 aneurysm sac measurement, is available 24/7 and could take into account all potential risk

17 factors for aneurysm sac development: technical problems (with persistent or new endoleaks),

18 aneurysm wall properties (potentially different biomechanical wall properties in patients with

19 atherosclerosis and genetic aortopathies), and pure influences of pre- and post-operative

20 thrombus volume after EVAR. Good quality data for sac evolution analysis to create AI is also

21 paramount, so it is possible that the algorithm will be biased by poor output data.[30-32] It could

22 be that some panel experts do not believe that accurate data will ever be available and that the

23 use of AI could ever be a comprehensive tool to analyse aneurysm sac evolution after EVAR.

24

1   *Study limitations.* This study must be interpreted within the context of its limitations. First, the

2   Delphi methodology has accepted inherent shortcomings. Delphi studies have been criticized

3   because the included items are chosen by the researchers, thereby potentially introducing bias.

4   Second, since random selection was not feasible, because of the experts' inclusion criteria, a

5   large pre-selected group of international experts proposed by the Core Team was invited,

6   potentially introducing selection bias since they might not fully represent the real worldwide

7   expertise, and results might also be partly influenced by local regulations and hospital policies.

8   Third, the strength of consensus among experts is often considered to represent the same level

9   of evidence as literature-based guidelines, although this might not necessarily hold true because

10 guidelines, which are graded with a definition of strength recommendations, are based on

11 literature analysis, whereas consensuses derived from the Delphi process can only be indicative

12 of hints at good practice. Nonetheless, for clinical scenarios in which high-quality evidence

13 may be difficult to obtain, the recommendations derived from a large body of experts may be

14 seen as an important adjunct to support decision-making. To mitigate this limitation, whenever

15 present, clinical practice guidelines from recognized scientific societies were consulted to

16 ensure that the proposed statements would not be discordant.

17

18 **References**

19 1.   Antoniou GA, Antoniou SA, Torella F. Editor's Choice - Endovascular vs. Open Repair

20   for Abdominal Aortic Aneurysm: Systematic Review and Meta-analysis of Updated Peri-

21   operative and Long Term Data of Randomised Controlled Trials. Eur J Vasc Endovasc

22   Surg. 2020;59:385-397.

23 2.   Mani K, Lees T, Beiles B, Jensen LP, Venermo M, Simo G et al. Treatment of abdominal

24   aortic aneurysm in nine countries 2005-2009: a vascunet report. Eur J Vasc Endovasc

25   Surg. 2011;42:598-607.

3. Schermerhorn ML, Buck DB, O'Malley AJ, Curran T, McCallum JC, Darling J et al. Long-Term Outcomes of Abdominal Aortic Aneurysm in the Medicare Population. N Engl J Med. 2015;373:328-338.

4. Chaikof EL, Dalman RL, Eskandari MK, Jackson BM, Lee WA, Mansour MA, Mastracci TM, Mell M, Murad MH, Nguyen LL, Oderich GS, Patel MS, Schermerhorn ML, Starnes BW. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. J Vasc Surg. 2018;67(1):2-77.

5. Wanhainen A, Van Herzeele I, Bastos Goncalves F, Bellmunt Montoya S, Berard X, Boyle JR, et al. Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms. Eur J Vasc Endovasc Surg. 2024;67:192-331

6. Geraedts ACM, Mulay S, Vahl AC, Verhagen HJM, Wisselink W, de Mik SML et al. Editor's Choice - Post-operative Surveillance and Long Term Outcome after Endovascular Aortic Aneurysm Repair in Patients with an Initial Post-operative Computed Tomography Angiogram Without Abnormalities: the Multicentre Retrospective ODYSSEUS Study. Eur J Vasc Endovasc Surg. 2022;63:390-399.

7. Houbballah R, Majewski M, Becquemin JP. Significant sac retraction after endovascular aneurysm repair is a robust indicator of durable treatment success. J Vasc Surg. 2010;52:878-883.

8. Lee JT, Aziz IN, Lee JT, Haukoos JS, Donayre CE, Walot I et al. Volume regression of abdominal aortic aneurysms and its relation to successful endoluminal exclusion. J Vasc Surg. 2003;38:1254-1263.

9. Bastos Gonçalves F, Baderkhan H, Verhagen HJ, Wanhainen A, Björck M, Stolker RJ et al. Early sac shrinkage predicts a low risk of late complications after endovascular aortic aneurysm repair. Br J Surg. 2014;101:802-810.

1 10. Antoniou GA, Alfahad A, Antoniou SA, Torella F. Prognostic Significance of Aneurysm

2   Sac Shrinkage After Endovascular Aneurysm Repair. J Endovasc Ther. 2020;27:857-

3   868.

4 11. Ikeda S, Sato T, Kawai Y, Tsuruoka T, Sugimoto M, Niimi K et al. One-year sac

5   regression is associated with freedom from fatal adverse events after endovascular

6   aneurysm repair. J Vasc Surg. 2023;77:136-142.e2.

7 12. D'Oria M, Bertoglio L, Bignamini AA, Mani K, Kölbel T, Oderich G et al. Editor's

8   Choice - PRINciples of optimal antithrombotiC therapy and coagulation managEment

9   during elective fenestrated and branched EndovaScular aortic repairS (PRINCE^{2}SS): An

10   International Expert Based Delphi Consensus Study. Eur J Vasc Endovasc Surg.

11   2022;63:838-850.

12 13. de la Fuente R, Fuentes R, Munoz-Gama J, Dagnino J, Sepúlveda M. Delphi Method to

13   Achieve Clinical Consensus for a BPMN Representation of the Central Venous Access

14   Placement for Training Purposes. Int J Environ Res Public Health. 2020;17:3889.

15 14. Dua A, Desai SS, Seabrook GR, Brown KR, Lewis BN, Rossi PJ et al. The effect of

16   Surgical Care Improvement Project measures on national trends on surgical site

17   infections in open vascular procedures. J Vasc Surg. 2014;60:1635-1639.

18 15. Schanzer A, Messina L. Two decades of endovascular abdominal aortic aneurysm repair:

19   enormous progress with serious lessons learned. J Am Heart Assoc. 2012;1:e000075.

20 16. Karthikesalingam A, Page AA, Pettengell C, Hinchliffe RJ, Loftus IM, Thompson MM

21   et al. Heterogeneity in surveillance after endovascular aneurysm repair in the UK. Eur J

22   Vasc Endovasc Surg. 2011;42:585-590.

23 17. O'Donnell TFX, Deery SE, Boitano LT, Siracuse JJ, Schermerhorn ML, Scali ST et al.

24   Aneurysm sac failure to regress after endovascular aneurysm repair is associated with

25   lower long-term survival. J Vasc Surg. 2019;69:414-422.

1   18.   Rastogi V, O'Donnell TFX, Marcaccio CL, Patel PB, Varkevisser RRB, Yadavalli SD et

2   al. One-year aneurysm-sac dynamics are associated with reinterventions and rupture

3   following infrarenal endovascular aneurysm repair. J Vasc Surg. 2023S0741-

4   5214(23)02092.

5   19.   Deery SE, Ergul EA, Schermerhorn ML, Sicaruse JJ, Schanzer A, Goodney PP et al.

6   Aneurysm sac expansion is independently associated with late mortality in patients

7   treated with endovascular aneurysm repair. J Vasc Surg. 2018;67:157-164.

8   20.   Fujimura N, Matsubara K, Takahara M, Harada H, Asami A, Shibutani S et al. Early sac

9   shrinkage is a good surrogate marker of durable success after endovascular aneurysm

10   repair in Japanese patients. J Vasc Surg. 2018;67:1410-1418.e1.

11   21.   Jetty P, Husereau D, Kansal V, Zhang T, Nagpal S. Variability in aneurysm sac regression

12   after endovascular aneurysm repair based on a comprehensive registry of patients in

13   Eastern Ontario. J Vasc Surg. 2019;70:1469-1478.

14   22.   Kirkham EN, Nicholls J, Wilson WRW, Cooper DG, Paravastu SCV, Kulkarni SR.

15   Safety and Validity of the Proposed European Society for Vascular Surgery Infrarenal

16   Endovascular Aneurysm Repair Surveillance Protocol: A Single Centre Evaluation. Eur

17   J Vasc Endovasc Surg. 2021;62:879-885.

18   23.   van der Laan MJ, Prinssen M, Bertges D, Makaroun MS, Blankensteijn JD. Does the type

19   of endograft affect AAA volume change after endovascular aneurysm repair. J Endovasc

20   Ther. 2003;10:406-410.

21   24.   Väärämäki S, Uurto I, Suominen V. Possible implications of device-specific variability

22   in post-endovascular aneurysm repair sac regression and endoleaks for surveillance

23   categorization. J Vasc Surg. 2023;78:1204-1211.

24   25.   Álvarez Marcos F, Llaneza Coto JM, Camblor Santervás LA, Zanabili Al-Sibbai AA,

25   Alonso Pérez M. Five Year Post Endovascular Aneurysm Repair Aneurysmal Sac

Evolution in the GREAT Registry: an Insight in Diabetics Using Propensity Matched Controls. Eur J Vasc Endovasc Surg. 2023S1078-5884(23)00878.

26. Mirza TA, Karthikesalingam A, Jackson D, Walsh SR, Holt PJ, Hayes PD, et al. Duplex ultrasound and contrast-enhanced ultrasound versus computed tomography for the detection of endoleak after EVAR: systematic review and bivariate meta-analysis. Eur J Vasc Endovasc Surg. 2010;39:418-28

27. Jean-Baptiste E, Feugier P, Cruzel C, Sarlon-Bartoli G, Reix T, Steinmetz E, et al. Computed Tomography-Aortography Versus Color-Duplex Ultrasound for Surveillance of Endovascular Abdominal Aortic Aneurysm Repair: A Prospective Multicenter Diagnostic-Accuracy Study (the ESSEA Trial). Circ Cardiovasc Imaging. 2020;13(6):e009886

28. Bissacco D, Mandigers TJ, Savaré L, Domanin M, D'Oria M, Ieva F, et al. Editor's Choice - Comparison of the Reproducibility of Ultrasound Calliper Placement Methods in Abdominal Aortic Diameter Measurements: A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies. Eur J Vasc Endovasc Surg. 2023;66:620-631

29. Adam C, Fabre D, Mougin J, Zins M, Azarine A, Ardon R et al. Pre-surgical and Post-surgical Aortic Aneurysm Maximum Diameter Measurement: Full Automation by Artificial Intelligence. Eur J Vasc Endovasc Surg. 2021;62:869-877.

30. Kiessling J, Brunnberg A, Holte G, Eldrup N, Sörelius K. Artificial Intelligence Outperforms Kaplan-Meier Analyses Estimating Survival after Elective Treatment of Abdominal Aortic Aneurysms. Eur J Vasc Endovasc Surg. 2023;65:600-607.

31. Caradu C, Pouncey AL, Lakhlifi E, Brunet C, Bérard X, Ducasse E. Fully automatic volume segmentation using deep learning approaches to assess aneurysmal sac evolution after infrarenal endovascular aortic repair. J Vasc Surg. 2022;76:620-630.e3.

1   32. Raffort J, Adam C, Carrier M, Ballaith A, Coscas R, Jean-Baptiste E et al. Artificial

2   intelligence in abdominal aortic aneurysm. J Vasc Surg. 2020;72:321-333.e1.

3

4

1 **Collaborative study group (PubMed indexed list – in alphabetical order):**

2 1. Adam W. Beck, University of Alabama at Birmingham Division of Vascular Surgery and

3   Endovascular Therapy - awbeck@uabmc.edu

4 2. Adrien Hertault, Department of Vascular and Endovascular Surgery, Ramsay Santé, Hôpital

5   Privé de Villeneuve d'Ascq, France - adhertault@hotmail.com

6 3. Ajay Savlania, Department of General Surgery, Post Graduate Institute of Medical

7   Education and Research, Chandigarh, India - drajaysavlania@gmail.com

8 4. Alberto Froio, Vascular Surgery, San Gerardo Teaching Hospital, University of Milano-

9   Bicocca - alberto.froio@unimib.it

10 5. Alessia Giaquinta, Vascular Surgery and Organ Transplant Unit, General Surgery and

11   Medical-Surgical Specialties Department, University Hospital of Catania, Italy -

12   alessiagiaquinta@gmail.com

13 6. Alexander   Zimmermann,   Department   of   Vascular   Surgery   -

14   alexander.zimmermann@usz.ch

15 7. Anastasios Psyllas, Marien-Hospital, Wesel, Germany - vstpsyllas@gmail.com

16 8. Anders Wanhainen, Department of Surgical Sciences, Vascular Surgery, Uppsala

17   University, Uppsala, Sweden - Anders.Wanhainen@surgsci.uu.se

18 9. Andrea Ascoli Marchetti, Vascular Surgery Unit Tor Vergata University Rome -

19   ascolimarchetti@med.uniroma2.it

20 10. Andre Brito Queiroz, Universidade Federal da Bahia, Salvador-Bahia-Brazil -

21   andrebrito01@hotmail.com

22 11. Andrea Kahlberg, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy -

23   kahlberg.andrea@hsr.it

24 12. Andrés Reyes-Valdivia, Ramon y Cajal University Hospital, Madrid, Spain -

25   cauzaza@hotmail.com

22

13. Andres Schanzer, University of Massachusetts Medical School - Andres.Schanzer@umassmemorial.org

14. Andrew Tambyraja Edinburgh Vascular, Royal Infirmary of Edinburgh, United Kingdom - andrew.tambyraja@nhslothian.scot.nhs.uk

15. Antonio Freyrie, Vascular Surgery, Dpt of Medicine and Surgery, University of Parma, Parma – Italy - antonio.freyrie@unipr.it

16. Antonio Lorido, Vascular and endovascular Unit. Belcolle Hospital. ASL Viterbo - Alorido@libero.it

17. Antoine Millon, Department of Vascular and Endovascular Surgery, University Hospital of Lyon, France - antoinemillon@hotmail.com

18. Arnaldo Ippoliti, Tor Vergata University, Rome, Italy - ippoliti@uniroma2.it

19. Babak Abai, Division of Vascular Surgery, Thomas Jefferson University, Philadelphia, PA - babak.abai@jefferson.edu

20. Barend Mees, Department of Vascular Surgery, Maastricht UMC+ - barend.mees@mumc.nl

21. Benedikt Reutersberg, MD, FEBVS, Department of Vascular Surgery, University hospital Zurich, Zurich, Switzerland - benedikt.reutersberg@usz.ch

22. Blandine Maurel, Dpt of Vascular Surgery, CHU Nantes, France - blandine.maurel@chu-nantes.fr

23. Bosiers Michel, Department of Vascular Surgery, University Hospital Bern, University of Bern, Bern, Switzerland - michel.bosiers@insel.ch

24. Carl Magnus Wahlgren, Department of Vascular Surgery, Karolinska University Hospital, Stockholm, Sweden - Carl.wahlgren@sll.se

25. Carlo Cavazzini, Vascular and Endovascular Department - IDI IRCCS – Rome - C.Cavazzini@idi.it

26. Carlo Setacci, Department of Medicine, Surgery and Neuroscience, Vascular and Endovascular Surgery Unit, University of Siena, Siena, Italy - carlo.setacci@unisi.it

27. Cheong Jun Lee, Northshore University Healthsystem and University of Chicago, Evanston, USA - clee6@northshore.org

28. Ciro Ferrer, Vascular Surgery Unit - San Giovanni Addolorata Hospital - cfrrr83@gmail.com

29. Colin Bicknell, Imperial Vascular Unit, London - colin.bicknell@nhs.net

30. Coscas Raphaël, Prof., Ambroise Paré Hospital AP-HP, Paris-Saclay University - rcoscas@gmail.com

31. Daniel Clair, Vanderbilt University Medical Center - dan.clair@vumc.org

32. David L. Dawson, Baylor Scott & White Health, Temple, Texas, USA - David.Dawson@BSWHealth.org

33. Dean J. Arnaoutakis, Division of Vascular Surgery, University of South Florida, Tampa, Florida, USA - arnaoutakis@usf.edu

34. Dittmar Böckler, University Hospital Heidelberg, Germany - dittmar.boeckler@med.uni-heidelberg.de

35. Drosos Kotelis, Department of Vascular Surgery, University Hospital of Bern, Bern, Switzerland- drosos.kotelis@insel.ch

36. Edin Mujagic, Vascular Surgery, University Hospital Basel, Switzerland - edin.mujagic@usb.ch

37. Emiliano Chisci, Department of Surgery, Vascular and Endovascular Surgery Unit, Florence, Italy - e.chisci@gmail.com

38. Enrico Cieri, Vascular and Endovascular Surgery Unit, University of Perugia, Italy - enrico.cieri@unipg.it

39. Enrico Gallitto, Vascular Surgery, University of Bologna, Bologna, Italy - enrico.gallitto@gmail.com

40. Enrico Maria Marone, Department of Clinical, Surgical, Diagnostic and Pediatric Sciences. University of Pavia. Department of Vascular Surgery. Policlinico di Monza Group - enricomaria.marone@gmail.com

41. Eric Ducasse, Service de Chirurgie Vasculaire, Hopital pellegrin, CHU de bordeaux place Amélie Raba Léon, 33076 Bordeaux, France - eric.ducasse@chu-bordeaux.fr

42. Fabio Verzini, Vascular Surgery Unit, Dept of Surgical Sciences, University of Turin - fabio.verzini@unito.it

43. Felice Pecoraro, Department of Surgical Oncological and Oral Sciences, University of Palermo, Vascular Surgery Unit, Azienda Ospedaliera Universitaria Policlinico 'P. Giaccone', Palermo, Italy - felice.pecoraro@unipa.it

44. Ferdinand Serracino-Inglott, Manchester Vascular Centre, Manchester Academic Health Science Centre, Manchester Royal Infirmary, Oxford Road, Manchester, UK - Ferdinand.serracino-inglott@mft.NHs.uk

45. Filippo Benedetto, Department BIOMORF, Vascular Surgery Unit ,University of Messina Italy - dott.filippobenedetto@gmail.com

46. Francesco Speziale, Vascular and Endovascular Surgery Unit, Department of Surgery, Sapienza University of Rome, Italy - francesco.speziale@uniroma1.it

47. Francesco Stilo, Unit of Vascular Surgery, Campus Bio-Medico University, Rome, Italy f.stilo@unicampus.it

48. Francisco Álvarez-Marcos, Vascular Surgery Department, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain - franalmar@gmail.com

49. Gabriele Pagliariccio, Vascular Surgery Department, Asl Teramo, Italy - gabriele.pagliariccio@gmail.com

1 50. Gabriele Piffaretti, Vascular Surgery - Department of Medicine and Surgery, University of
2   Insubria School of Medicine - gabriele.piffaretti@uninsubria.it

3 51. Gaetano Lanza, Vascular Surgery Unit, Castellanza, Italy, gaetano.lanza@multimedica.it

4 52. Geisbüsch, Philipp, Department of Vascular and Endovascular Surgery, Klinikum Stuttgart
5   - p.geisbuesch@klinikum-stuttgart.de

6 53. George Geenberg, Soroka University MC, Beer Sheva, Israel - drgeorgegr51@gmail.com

7 54. Georg Jung, Luzerner Kantonsspital - georg.jung@luks.ch

8 55. Germano Melissano, Ospedale San Raffaele Milano, Italy - melissano.germano@hsr.it

9 56. Gian Franco Veraldi, University Hospital and Trust of Verona - Department of Surgery -
10   Unit of Vascular and Endovascular Surgery - Verona - Italy -
11   gianfranco.veraldi@aovr.veneto.it

12 57. Gianbattista Parlani, Unit of Vascular & Endovascular Surgery S Maria Misericordia
13   Hospital Perugia, Italy - parlani.gianbattista@gmail.com

14 58. Gianluca Faggioli, Department of Vascular Surgery, IRCCS S. Orsola Malpighi Polyclinic,
15   DIMEC - University of Bologna, Bologna, Italy - gianluca.faggioli@unibo.it

16 59. Gianmarco de Donato, University of Siena, Italy - dedonato@unisi.it

17 60. Gioele Simonte, Vascular and Endovascular Surgery Unit, Azienda Ospedaliera di Perugia
18   - giosimonte@gmail.com

19 61. Giovanni Colacchio, Surgery Department-Vascular And Endovascular Surgery Unit-
20   Policlinico Universitario "F.Miulli", Acquaviva Delle Fonti (BA), Italy -
21   gm.colacchio@gmail.com

22 62. Giovanni De Caridi, Vascular Surgery Policlinico Universitario Messina -
23   giovanni.decaridi@unime.it

24 63. Giovanni Pratesi, Clinic of Vascular and Vascular Surgery - IRCCS Ospedale Policlinico
25   San Martino - University of Genova - giovanni.pratesi@unige.it

64. Giovanni Spinella, University of Genova - spinella.giovannisg@gmail.com

65. Giovanni Torsello, Vascular Surgery Franziskus Hospital Münster, Germany - giovanni.torsello@sfh-muenster.de

66. Glenn Wei Leong Tan, Vascular Surgery Service, Department of General Surgery, Tan Tock Seng Hospital, Singapore - glenn_tan@ttsh.com.sg

67. Gregory A. Magee, Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, University of Southern California, USA - gregory.magee@gmail.com

68. Hence Verhagen, Erasmus University Medical Center, vascular surgery, Rotterdam, the Netherlands - hence.verhagen@me.com

69. Holden, Andrew MBChB, FRANZCR, EBIR, Auckland Hospital - AndrewH@adhb.govt.nz

70. Issam Koleilat, Department of Surgery, RWJBH Community Medical Center, Tom's River, NJ, USA - ikoleilat@gmail.com

71. J Westley Ohman, Section of Vascular Surgery, Washington University, St. Louis, MO - ohmanj@wustl.edu

72. J.P.P.M. de Vries, Department of Surgery, Division of Vascular Surgery, University - Medical Centre Groningen, the Netherland - j.p.p.m.de.vries@umcg.nl

73. Jacob Budtz-Lilly, Aarhus University Hospital - jacoblilly@me.com

74. James Black, Johns Hopkins Hospital - jhblack@jhmi.edu

75. Jens Eldrup-Jorgensen, Division of Vascular Surgery, Maine Medical Center, Portland, Maine, USA - jjorgensen@svspso.org

76. Joe Hockley, Department of Vascular Surgery, Sir Charles Gairdner Hospital, Perth, Australia - Joseph.Hockley@health.wa.gov.au

77. Jonathan Bath, University of Missouri, Division of Vascular Surgery, Columbia, MO, USA - bathj@health.missouri.edu

78. Jonathan Sobocinski, CHU Lille, France - jonathan.sobo@gmail.com

79. Joost A. van Herwaarden, Dep. of Vascular Surgery, University Medical Center, Utrecht, The Netherlands - j.a.vanherwaarden@umcutrecht.nl

80. Kopp Reinhard, Department of Vascular Surgery, University Hospital Zurich - reinhard.kopp@usz.ch

81. Kristine C. Orion, The Ohio State University - kristine.orion@osumc.edu

82. Kwame Amankwah, UCONN Health Division of Vascular Surgery - Amankwah@uchc.edu

83. Luca Bertoglio, Division of vascular surgery, Department of Sperimental and Clinical Sciences University of Brescia School of Medicine Spedali Civili di Brescia, Italy - luca.bertoglio@unibs.it

84. Luca di Marzo, Sapienza University of Rome, Italy - luca.dimarzo@uniroma1.it

85. Luca Garriboli, Vascular Endovascular Surgery Unit, Negrar di Valpolicella, Italy - luca.garriboli@gmail.com

86. Luigi Rizzo, Vascular Surgery Unit, santandrea hospital, rome italy - luigi.rizzo@uniroma1.it

87. Maani Hakimi, Cantonal Hospital of Lucerne - Lucerne, Switzerland - maani.hakimi@luks.ch

88. Malachi Sheahan, Louisiana State University Health Sciences Center, New Orleans, LA, USA - msheah@lsuhsc.edu

89. Manar Khashram, Department of Vascular Surgery, Waikato Hospital, New Zealand - manar.khashram@gmail.com

90. Marc Schermerhorn, Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA - mscherm@bidmc.harvard.edu

91. Mario Lescan, Department of Thoracic and Cardiovascular Surgery, University Medical Centre Tübingen, Tübingen, Germany - mariolescan@icloud.com

92. Mark Conrad, Division of Vascular and Endovascular Surgery, Department of Surgery, Massachusetts General Hospitl, Boston, MA Mark.Conrad2@steward.org

93. Mark G Davies, Vascular and Endovascular Surgery, UT Health San Antonio, San Antonio , Texas, USA - mark.daviesmdphd@gmail.com

94. Martin Czerny, University Heart Center Freiburg - martin.czerny@universitaets-herzzentrum.de

95. Matteo Orrico, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy - dr.orrico.matteo@gmail.com

96. Matthew J. Eagleton, Massachusetts General Hospital, Boston, MA 02114, USA - MEAGLETON@mgh.harvard.edu

97. Matthew R. Smeds, Division of Vascular and Endovascular Surgery, Saint Louis University - matt.smeds@health.slu.edu

98. Maurizio Taurino, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, "La Sapienza" University of Rome, Italy - maurizio.taurino@uniroma1.it

99. Max Wohlauer, University of Colorado School of Medicine, Division of Vascular Surgery USA - Max.wohlauer@cuanschutz.edu

100. Mel J Sharafuddin, Department of Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA, USA - mel-sharafuddin@uiowa.edu

101. Menges, Anna-Leonie, Vascular Surgery, University Hospital Zurich, Switzerland - anna-leonie.menges@usz.ch

102. Michel Reijnen, Dept of Surgery, Rijnstate, Arnhem and Multi-modality Medical Imaging group, University of Twente, Enschede, The Netherlands - mmpj.reijnen@gmail.com

103. Michele Antonello, University of Padua, Italy - michele.antonello.1@unipd.it

104. Michele Piazza, Vascular and Endovascular Surgery Padua University - michele.piazza@unipd.it

105. Nicla Settembre, Nancy University Hospital, University of Lorraine - nicla.settembre@yahoo.com

106. Nicolas J Mouawad, MD MPH MBA, Division of Vascular and Endovascular Surgery, McLaren Health System, Bay City, MI - nmouawad@gmail.com

107. Nikolaos Tsilimparis, Department of Vascular Surgery, LMU Hospital, Munich, Bavaria Germany - Nikolaos.Tsilimparis@med.uni-muenchen.de

108. Nuno Dias, Vascular Center, Department of Thoracic and Vascular Surgery, Skåne University Hospital, Malmö, Sweden and Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden - nunovdias@gmail.com

109. Ombretta Martinelli, "Sapienza" University - "Umberto I" Hospital- Department of General and Specialist Surgery - Vascular Surgery Unit -Rome, Italy - ombretta.martinelli@uniroma1.it

110. Paolo Frigatti, Unit of Vascular and Endovascular Surgery, General Surgery Department, ASUFC, Hospital of Udine, Udine, Italy - paolo.frigatti@asufc.sanita.fvg.it

111. Pasqualino Sirignano, Department of General and Specialistic Surgery, "Sapienza" University of Rome - Vascular and Endovascular Surgery Division, Sant'Andrea Hospital of Rome - pasqualino.sirignano@uniroma1.it

112. Patrick Chong, Regional Unit for Vascular Surgery, Frimley Health NHS Foundation Trust, United Kingdom - patrickchong@nhs.net

113. Paul Bevis, North Bristol NHS Trust - Paul.bevis@nbt.nhs.uk

114. Paul DiMuzio, Thomas Jefferson University, Philadelphia, Pennsylvania, USA - paul.dimuzio@jefferson.edu

115. Peter Henke, university of Michigan - henke@umich.edu

116. Philip Düppers, Department for Vascular Surgery, University Hospital Zurich - philip.dueppers@usz.ch

117. Peter Holt, St George's, London, UK - Peter.Holt2@stgeorges.nhs.uk

118. Päivi Helmiö, Vascular Surgery Tyks - Turku University Hospital - paivi.helmio@tyks.fi

119. Patrick Vriens, Elisabeth TweeSteden Ziekenhuis Tilburg, The Netherlands - pwhe.vriens@etz.nl

120. Raffaele Pulli, Vascular Surgery Unit, University of Florence, Italy - raffaele.pulli@unifi.it

121. Raffaello Bellosta, Vascular & Endovascular Surgery, Poliambulanza Foundation Hospital - raffaello.bellosta@poliambulanza.it

122. Raimondo Micheli, Unit of Vascular Surgery."S.Mary" Hospital, Terni, Italy - rai.micheli@gmail.com

123. Ravi Veeraswamy, The Medical University of South Carolina - veeraswa@musc.edu

124. Robert Cuff, Spectrum Health, Grand Rapids, MI USA - robert.cuff@spectrumhealth.org

125. Roberto Chiappa, UOC Chirurgia Vascolare Ospedale Sandro Pertini, ASL Roma 2, Roma - robchiap@gmail.com

126. Roberto Gattuso - Vascular Surgery Division, Department of Surgery "Paride Stefanini", Policlinico Umberto I - "La Sapienza" University of Rome, Rome, Italy - roberto.gattuso@uniroma1.it

127. Rodolfo Pini, Department of Vascular Surgery, IRCCS S. Orsola Malpighi Polyclinic, DIMEC - University of Bologna, Bologna, Italy - rudypini@gmail.com

128. Ronald L. Dalman, Stanford University - rld@stanford.edu

129. Ross Milner, University of Chicago Medicine - rmilner@surgery.bsd.uchicago.edu

130. Salvatore T. Scali, Division of Vascular Surgery and Endovascular Therapy, University of Florida, United States - Salvatore.Scali@surgery.ufl.edu

131. Sandeep Bahia, East Kent Hospitals, UK - sandeep.bahia@nhs.net

132. Sani Laukontaus, Department of Vascular Surgery, Helsinki University Hospital, Finland - sani.laukontaus@gmail.com

133. Santi Trimarchi, Cardio Thoraco Vascular Dept, Unit of Vascular Surgery, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico Milan, University of Milan - santi.trimarchi@unimi.it

134. Sebastian Fernandez-Alonso, Vascular Surgery. Hospital Universitario de Navarra. Pamplona. Spain - sebasfern@gmail.com

135. Sebastien Deglise, Vascular Surgery, Lausanne University Hospital (CHUV; Lausanne, Switzerland) - sebastien.deglise@chuv.ch

136. Sergi Bellmunt-Montoya, Vascular Surgery, Hospital Vall d'Hebron. Barcelona, Spain - sergi.bellmunt@vallhebron.cat

137. Simone Hofer, Department of Surgery, Vascular Unit - Simone.Hofer@ksgr.ch

138. Syed W Yusuf, Department of Vascular Surgery University Hospitals Sussex - syed.yusuf1@nhs.net

139. Sonia Ronchey, Vascular Surgery Department - Asl Roma1 - San Filippo Neri Hospital - sonia.ronchey@gmail.com

140. Stefano Bartoli, Roma - steba08@gmail.com

141. Stefano Bonvini, Vascular and endovascular surgery division, APSS Trento - stefano.bonvini@apss.tn.it

142. Stefano Camparini, Chirurgia Vascolare, ARNAS G.Brotzu, Cagliari, Italia - stefanocamparini@aob.it

143. Stefano Fazzini, Vascular Surgery, Tor Vergata University of Rome, Rome, Italy - dr.stefano.fazzini@gmail.com

144. Stefano Pirrelli, Vascular Surgery - Dept. Cardiovascular - Asst Papa Giovanni XXIII-Bergamo - spirrelli@asst-pg23.it

145. Tal Hörer, Örebro University hospital, Sweden - tal.horer@regionorebrolan.se

146. Theodosios Bisdas, Clinic Of Vascular Surgery, Athens Medical Center, Athens Greece - th.bisdas@gmail.com

147. Thodur Vasudevan, Alfred Hospital, Melbourne, Australia - t.vasudevan@alfred.org.au

148. Thomas Lattmann, Cantonal Hospital Wintherthur, Switzerland - thomas.lattmann@ksw.ch

149. Thomas Rudolf Wyss, MD, Department of Vascular Surgery, Kantonsspital Winterthur, Winterthur, Switzerland - thomas.wyss@ksw.ch

150. Thomas Maldonado, New York University Langone Health - Thomas.Maldonado@nyumc.org

151. Thomas Pfammatter, Zurich University Hospital, Dept of radiology - thomas.pfammatter@usz.ch

152. Tilo Kölbel, German Aortic Center, University Medical Center Eppendorf, Hamburg, Germany - tilokoelbel@googlemail.com

153. Tomasz Jakimowicz, Department of General, Vascular and Transplant Surgery, Medical University of Warsaw, Poland - tomj@wum.edu.pl

154. Tommaso Donati, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy - tommaso.donati@policlinicogemelli.it

155. Margaret Tracci, University of Virginia, Charlottesville, VA, USA - msc7s@hscmail.mcc.virginia.edu

156. Umberto Marcello Bracale, Vascular Surgery Unit, Department of Public Health, University Federico II of Naples, Naples, Italy - umbracale@gmail.com

157. Valerio Stefano Tolva, Fondazione "A. De Gasperis", Dipartimento Cardiotoracovascolare. Vascular Surgery Unit, Milan, Italy - v.tolva@auxologico.it

158. Vincent Riambau, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain - vriambau@gmail.com

159. Vincenzo Palazzo, Unit Of Vascular Surgery - IRCCS " Casa Sollievo Della Sofferenza " - San Giovanni Rotondo (FG) – Italy, palaenzo@katamail.com

160. Vladimir Makaloski, Department of Vascular Surgery, University Hospital Bern, Inselspital, University of Bern - Vladimir.Makaloski@insel.ch

161. Von Allmen Regula S, Clinics for Vascular Surgery, Kantonsspital St. Gallen, Switzerland - regula.vonallmen@kssg.ch

162. Walter Dorigo, Vascular Surgery, Department of Cardiothoracic and Vascular Surgery, Careggi University Teaching Hospital, Florence, Italy - walter.dorigo@unifi.it

163. Wassim Mansour, Department of general and specialized surgery, Unit of Vascular Surgery, Sapienza University of Rome, Rome, Italy - wassim.mansour@uniroma1.it

164. Wouter Van den Eynde, Department of Vascular and Thoracic Surgery, Imelda hospital Bonheiden, Belgium - wouter_vandeneynde@hotmail.com

Table I: Strength and consistency grading definitions for statement submitted to the experts panel during the Delphi rounds.

Grade	Rating	Definition
A	Very strong	Full agreement ≥75%
B	Strong	Full agreement <75% Overall agreement ≥80% Full disagreement <5%
C	Fair	Full agreement <75% Overall agreement ≥80% Full disagreement ≥5%
D	Poor	Full disagreement ≥10%
Consistency	**Rating**	**Definition**
I	Very high	Cohen's k p value ≤ .001 Intraclass correlation p value ≤ .001
II	High	Cohen's k and intraclass correlation coefficient p value ≤ .001 in one and ≤ .01 in the other analysis
III	Fair	Cohen's k p value > .05 Fleiss's k p value ≤ .0001
IV	Poor	Cohen's k p value > .05 Fleiss's k p value >.01

Table II: Proportion of consensus obtained by each statement at the third round.

Statement	Full agreement %	Overall agreement %	Full disagreement %	Mean	SD	Wilcoxon's test p value	Pearson correlation	Final grade
1	85.63	97.70	0.57	1.172	0.461	0.212	<0.0001	A
2	83.33	96.55	2.30	1.224	0.58	0.880	<0.0001	A
3	75.29	97.70	0.57	1.276	0.52	0.048	1.000	A
4	85.06	97.13	0.57	1.184	0.482	0.396	<0.0001	A
5	90.23	98.85	0.57	1.115	0.385	0.644	0.3466	A
6	77.01	97.70	0.57	1.259	0.512	0.241	0.0247	A
7	71.84	98.28	0.57	1.305	0.52	0.058	<0.0001	B
8	79.31	97.13	0.57	1.241	0.515	0.844	<0.0001	A
10	75.86	91.38	2.87	1.356	0.721	0.029	1.000	A
11	79.31	95.98	1.15	1.259	0.566	0.201	<0.0001	A
12	81.61	97.13	0	1.213	0.476	0.465	<0.0001	A
13	80.46	95.40	0.57	1.247	0.55	0.738	0.0007	A
14	78.16	94.25	1.15	1.287	0.606	0.094	<0.0001	A
15	95.40	99.43	0.57	1.057	0.299	0.146	<0.0001	A
16	87.93	98.28	0	1.138	0.393	0.110	1.000	A
17	89.08	99.43	0	1.115	0.337	0.393	<0.0001	A
18	83.91	97.70	0	1.184	0.444	0.687	<0.0001	A
19	78.74	97.70	0	1.236	0.477	0.012	0.0011	A
20	74.71	93.68	2.87	1.345	0.686	0.014	1.000	B
21	63.79	94.83	1.72	1.431	0.648	0.839	<0.0001	B
22	66.67	97.70	0.57	1.362	0.549	0.858	<0.0001	B
23	87.36	98.28	0.57	1.149	0.431	0.460	<0.0001	A
24	74.71	93.10	0.57	1.328	0.619	0.402	<0.0001	B
25	68.39	91.95	2.30	1.42	0.707	0.402	0.4080	B
26	68.97	91.38	2.30	1.42	0.715	0.991	<0.0001	B
28	74.71	96.55	1.72	1.305	0.593	0.8490	<0.0001	B
29	73.56	97.13	0.57	1.299	0.54	0.587	<0.0001	B

Table III: Overall consistency across rounds estimated using Cohen's kappa and Fleiss' pi evaluation

Statement	Agreement %	Cohen's Kappa		Fleiss Pi		Intraclass Correlation		Test-retest	Overall consistency
		Coeff.	P value	Coeff.	P value	Coeff. (95%CI)	P value		
1	0.874	0.564	<0.001	0.564	<0.001	0.628 (0.529-0.71)	<0.001	12.64	II
2	0.833	0.429	<0.001	0.440	<0.001	0.474 (0.351-0.582)	<0.001	2.87	I
3	0.684	0.277	<0.001	0.277	<0.001	0.198 (0.051-0.336)	0.004	5.17	I
4	0.828	0.398	<0.001	0.402	<0.001	0.493(0.372-0.598)	<0.001	9.20	I
5	0.862	0.277	0.006	0.288	0.004	0.292 (.15-.422)	<0.001	13.79	II
6	0.782	0.346	<0.001	0.346	<0.001	0.323 (.184-.45)	<0.001	9.20	I
7	0.770	0.386	<0.001	0.380	<0.001	0.453 (.327-.563)	<0.001	8.62	I
8	0.805	0.432	<0.001	0.434	<0.001	0.453 (.327-.564)	<0.001	3.45	I
10	0.626	0.196	0.002	0.185	0.004	0.224 (.0782-.36)	0.001	8.05	II
11	0.782	0.426	<0.001	0.421	<0.001	0.635 (0.537-0.716)	<0.001	7.47	I
12	0.776	0.322	<0.001	0.317	<0.001	0.491 (0.369-.0595)	<0.001	9.20	I
13	0.741	0.237	0.002	0.238	0.002	0.385 (.251-.504)	<0.001	2.87	II
14	0.707	0.289	<0.001	0.287	<0.001	0.412 (0.281-0.528)	<0.001	6.32	I
15	0.919	0.349	0.003	0.367	0.003	0.457 (0.332-0.567)	<0.001	8.05	II
16	0.805	0.260	0.003	0.263	0.003	0.242 (0.098-0.377)	0.001	2.87	II
17	0.851	0.320	0.001	0.315	0.001	0.411 (0.28-0.527)	<0.001	14.94	II
18	0.828	0.350	<0.001	0.355	<0.001	0.461 (0.336-0.57)	<0.001	17.24	II
19	0.741	0.381	<0.001	0.385	<0.001	0.347 (0.209-0.471)	<0.001	3.45	I
20	0.661	0.291	<0.001	0.281	<0.001	0.237 (0.092-0.372)	0.001	9.20	I
21	0.776	0.540	<0.001	0.541	<0.001	0.511 (0.393-0.613)	<0.001	2.30	I
22	0.701	0.356	<0.001	0.359	<0.001	0.47 (0.346-0.578)	<0.001	1.15	I
23	0.879	0.412	<0.001	0.406	<0.001	0.557 (0.445-0.651)	<0.001	12.07	II
24	0.753	0.326	<0.001	0.319	<0.001	0.432 (0.303-0.545)	<0.001	2.87	I
25	0.632	0.188	0.002	0.186	0.003	0.29 (0.149-0.42)	<0.001	6.90	II
26	0.649	0.253	<0.001	0.253	<0.001	0.452 (0.325-0.562)	<0.001	4.60	I
28	0.793	0.466	<0.001	0.475	<0.001	0.612 (0.51-0.697)	<0.001	20.69	II
29	0.770	0.408	<0.001	0.404	<0.001	0.569(0.46-0.661)	<0.001	22.99	II

Table IV: Complete text of the 27 statements submitted to the fourth round.

Statement number	Statement	Grade	Consistency
1	Sac regression definition Sac regression should be defined as reduction in maximum diameter of the aneurysm sac by ≥ 5 mm	A	II
2	Sac regression role Aneurysm sac regression should be considered an important indicator of EVAR success.	A	I
3	Sac Regression and endoleak Aneurysm sac regression is usually correlated to the absence of endoleaks that require secondary intervention after EVAR.	A	I
4	Sac Regression and endoleak Aneurysm sac regression is usually correlated to the absence of type I and III endoleaks after EVAR.	A	I
5	Sac Regression and aneurysm rupture Aneurysm sac regression is correlated to low rates of aneurysm rupture after EVAR.	A	II
6	Sac Regression and secondary intervention Aneurysm sac regression is usually correlated to low rates of secondary intervention after EVAR.	A	I
7	Sac Regression and aneurysm-related complications	B	I

	Aneurysm sac regression is usually correlated to low rates of aneurysm-related complications after EVAR.		
8	Sac Regression and aneurysm-related mortality Aneurysm sac regression is usually correlated to reduced aneurysm-related mortality after EVAR.	A	I
10	Follow-up The first follow-up after discharge of elective EVAR should be a DUS or CT-angiography within 3 months.	A	II
11	Follow-up At 1-year follow-up, the imaging modality should be a DUS or a CTA (if DUS is not available or not diagnostic).	A	I
12	Follow-up At 2-year follow-up, the imaging modality should be a DUS or a CTA (if DUS is not available or not diagnostic).	A	I
13	Follow-up At 3-year follow-up, the imaging modality should be a DUS or a CTA (if DUS is not available or not diagnostic).	A	II
14	Follow-up At 5-year follow-up, the imaging modality should be a DUS or a CTA (if DUS is not available or not diagnostic).	A	I
15	Sac Regression assessment	A	II

	Sac regression should always be assessed during follow-up after EVAR.		
16	Sac regression assessment A Duplex Ultrasound (DUS) or a CTA should be used as first-line imaging modality to assess sac regression during follow-up.	A	II
17	Sac regression assessment The comparison of two CTA (baseline vs follow-up) is the most accurate imaging to detect sac regression after EVAR.	A	II
18	Sac regression assessment In case of DUS imaging modality, the sac regression should be measured in two projections at least (AL and PP).	A	II
19	Sac regression assessment In case of CTA imaging modality, the sac regression should be measured on the orthogonal axis using a dedicated reconstruction software.	A	I
20	Sac regression assessment The baseline imaging used to assess sac regression after EVAR should be the pre-operative CTA (done within 6 months before EVAR) or the first post-operative DUS or CTA (done within 3 months after EVAR).	B	I
21	Sac regression follow-up	B	I

	Sac regression can be usually expected to occur within 2 years after EVAR.		
22	Sac stable: role Sac stability (diameter change within ± 4.9 mm) may be considered a clinically relevant parameter during follow-up after EVAR.	B	I
23	Sac increase: role Sac increase (diameter change ≥ 5 mm) should be considered a clinically relevant parameter during follow-up after EVAR.	A	II
24	Sac regression: role In case of sac regression, the follow-up protocol after EVAR should be continued.	B	I
25	Sac regression: role In case of sac regression, the follow-up protocol after EVAR may be modified according to case-specific features (e.g. on-IFU vs off-IFU, age of the patient, chronic anticoagulation, etc).	B	II
26	Sac regression: exception In case of EVAR within the IFU, sac regression is one of the parameters to consider for possible follow-up protocol changes.	B	I
28	Follow-up: adjunctive tools	B	II

	Volumetric analysis may represent, in the future, an adjunctive tool to analyze AAA sac evolution during follow-up after EVAR.		
29	Follow-up: adjunctive tools Artificial Intelligence and Machine Learning may represent, in the future, an adjunctive tool to analyze sac evolution during follow-up after EVAR.	B	II